Tag: Motley Fool

  • Why the WiseTech Global (ASX:WTC) share price is climbing higher today

    Graphic representation of internet of things

    The WiseTech Global Ltd (ASX: WTC) share price is climbing higher following the release of its annual general meeting presentation.

    At the time of writing, the logistics solutions company’s shares are up 2% to $30.73.

    What happened at the WiseTech Global AGM?

    As with all annual general meetings, the company started by providing investors with a reminder of how it performed in FY 2020.

    For the 12 months ended 30 June, WiseTech Global delivered a 23% increase in revenue to $429.4 million. This was driven by a combination of acquisitions and its core CargoWise offering.

    The latter continued its strong growth and recorded revenue of $263 million, up 20% on FY 2019. Management advised that this reflects new customer signings and increased usage by existing customers.

    On the bottom line, excluding a fair value gain of $111 million, its underlying net profit after tax was flat at $52.6 million. This was due to increased depreciation and amortisation expenses from its increased investment in research and development and the amortisation from acquisition product development.

    What is expected in FY 2021?

    In August, WiseTech provided full year guidance for revenue of $470 million to $510 million and earnings before interest, tax, depreciation and amortisation (EBITDA) of $155 million to $180 million.

    This represents growth in the range of 9% to 19% and 22% to 42%, respectively, year on year.

    This morning WiseTech has reaffirmed this guidance. However, it has warned that the ongoing and longer-term impacts of COVID-19 are still not completely predictable.

    One thing management is much more certain on is its long term growth prospects beyond COVID-19.

    WiseTech’s CEO, Richard White, commented: “Looking ahead, with penetration of automated, truly global logistics solutions still in early stages, WiseTech’s opportunity for growth is vast. We believe CargoWise is the market-leading platform for global logistics execution and is well-positioned to strengthen its position in the global market over the near-term and long-term.”

    “… longer term, COVID-19 market disruptions have provided a tailwind for growing our market share as the need for digitalisation across the global logistics execution market accelerates and significantly increases the value and demand for CargoWise,” he added.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of WiseTech Global. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the WiseTech Global (ASX:WTC) share price is climbing higher today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/37cfvh1

  • The real earnings growth driver for ASX bank stocks in FY21 isn’t what you think

    ASX banks Profits Growth - Make Money

    The Virgin Money UK CDI (ASX: VUK) share price will be on watch this morning after the bank posted a big drop in FY20 profit.

    But don’t be too caught up in the profit numbers. The real growth driver for the sector isn’t what you think.

    The announcement comes on the day that the S&P/ASX 200 Index (Index:^AXJO) is expected to open softer along with other ASX banks.

    The UK lender unveiled a 77% crash in full year underlying net profit to £124 million ($225.5 million). This was largely driven by a huge increase in impairments to £501 million from £153 million in FY19.

    Virgin Money share price on edge

    But even ignoring impairments, operating profit fell 10% to £625 million due to margin squeeze and base rate cuts.

    The banks net interest margin (NIM) fell 10 basis points to 1.56%, while non-interest income declined due to lower activity.

    The key drag was a 3% drop in mortgage lending to £58.3 billion as the COVID‐19 lockdown in the UK impinged on the housing market.

    How much bad news is priced into ASX banks?

    This was offset somewhat by growth in business lending (up 13.6%) and personal lending (up 3.9%). But lending to these two segments only amounted to around £14 billion in total.

    However, the weak results won’t surprise anyone. It’s much the same story when ASX banks turned in their earnings report cards.

    The National Australia Bank Ltd. (ASX: NAB) share price, Westpac Banking Corp (ASX: WBC) share price and Australia and New Zealand Banking GrpLtd (ASX: ANZ) share price rallied despite the big profit drops.

    The key to ASX bank earnings growth isn’t lending

    This is because investors believe the worst is over for bank earnings. While earnings growth is likely to be missing in action in FY21, there’s an expectation that the large provisioning they put aside for bad debts will be lowered.

    This is an important point for investors. Every dollar that’s removed from impairments and provisions flows straight to net profit.

    Even if lending growth stagnates, bank earning can soar in FY21 if the banks can release some of the emergency funds they’ve put aside.

    We are starting to see signs of this. Commonwealth Bank of Australia (ASX: CBA) made such a move with the blessing of our banking regulator.

    In my view, this is what’s driving the re-rating in the banking sector.

    Foolish takeaway on the Virgin Money share price

    While Virgin Money operates in the UK and is driven by different factors, its huge impairments give it a lot of fat that can be moved back to its bottom line if economic conditions and confidence improve.

    This is good news for the Virgin Money share price as management painted a lacklustre outlook for FY21. Net interest margin is likely to be “broadly stable” this financial year, which to me means it could dip more.

    But with a number of promising COVID vaccines in the making, the UK economy could see a bounce back next year – just in time for Virgin Money to lower its impairments.

    Looking For Bargain Buys? These Cheap Stocks Could Be Just What You’re After (FREE REPORT)

    Scott Phillips has released a FREE stock report revealing 5 stocks that he believes are WAY undervalued by the market at these current prices.

    Scott thinks these 5 stocks are a ‘must consider’ for any savvy investor.

    Don’t miss out! Simply click the link below to grab your free copy and discover Scott’s 5 bargain stocks now.

    Click Here For Your Free Stock Report

    More reading

    Motley Fool contributor Brendon Lau owns shares of Australia & New Zealand Banking Group Limited, Commonwealth Bank of Australia, National Australia Bank Limited, and Westpac Banking. Connect with me on Twitter @brenlau.

    The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post The real earnings growth driver for ASX bank stocks in FY21 isn’t what you think appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3nRMlu4

  • Down 17%, is Apple stock a buy?

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    Falling Apple stock price represented by woman wearing face mask looking at products in Apple store

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    Following a huge run-up in 2019 and the first half of 2020, shares of Apple Inc (NASDAQ: AAPL) have taken a breather recently. The tech stock is down 17% from an all-time high of about $138 this summer.

    Is weakness in the tech giant’s stock a buying opportunity? Or should investors hope for an even bigger sell-off before they take a position in the iPhone maker?

    Apple’s business is stronger than ever

    It’s difficult to criticise Apple’s business. The company generated $275 billion of revenue in the trailing 12 months, up from $260 billion one year earlier. Meanwhile, Apple raked in an incredible $73 billion of free cash flow (cash from operations less capital expenditures).

    One potential critique an investor might bring up is the company’s decline in iPhone revenue in Apple’s most recent quarter. iPhone revenue fell 26% year over year during the period.  But Apple bulls would quickly point out that the tech company was up against an unfair comparison during the period since this year’s iPhone launch was delayed by pandemic-related supply chain challenges. In fact, if you rewind one quarter — when Apple wasn’t up against an unfair comparison — Apple demonstrated growth across every product segment and every geographic region. In the company’s most recent quarter, every segment other than the iPhone saw strong double-digit growth despite supply chain constraints for some products. Management went as far as to confidently forecast that its iPhone segment would return to growth during the current quarter.

    Then there’s Apple’s $192 billion of cash and marketable securities. Even when subtracting out low interest rate debt, excess cash is $79 billion.

    With both a strong business and a healthy balance sheet, the company is unsurprisingly returning lots of cash to shareholders. In the fourth quarter of fiscal 2020 alone, Apple returned $22 billion to shareholders through dividends and repurchases.

    But what about that pricey valuation?

    Apple’s demonstrating broad-based growth, generating more than $70 billion annually in free cash flow, and sitting on a mountain of cash. But is it worth $2 trillion? This is approximately where the company’s stock price today puts its market capitalisation.

    Unfortunately, even though Apple looks well positioned to deliver double-digit earnings growth in the coming years, the stock’s valuation is too steep to make this a no-brainer buy today. Shares currently trade at 35 times earnings — a steep premium that prices in strong growth for years to come.

    Sure, Apple stock may be a good buy for investors looking for dividend income. Apple currently has a dividend yield of 0.8%, and it’s grown that dividend payout every year since it was initiated in 2012. But for investors looking for strong share price appreciation over the next five years, it might be worth waiting to see if the stock falls further before buying.

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Daniel Sparks has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Apple. The Motley Fool Australia has recommended Apple. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Down 17%, is Apple stock a buy? appeared first on Motley Fool Australia.

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    from Motley Fool Australia https://ift.tt/376q6Kg

  • Origin Energy (ASX:ORG) share price on watch after investor update

    asx renewable energy shares represented by light bulb surrounded by green energy icons

    The Origin Energy Ltd (ASX: ORG) share price will be on watch today after the energy company released an investor update.

    What was included in the update?

    Origin’s update gave investors a summary on how it performed in FY 2020 and its expectations for FY 2021.

    In respect to the former, the company had a mixed year and delivered a flat underlying profit of $1,023 million in FY 2020. This was driven by lower corporate and LNG hedging costs being partly offset by a lower electricity margin.

    This led to the Origin board declaring a total dividend of 25 cents per share, which was also flat on the prior year.

    What is Origin expecting in FY 2021?

    This morning Origin reconfirmed its Energy Markets guidance for FY 2021.

    It continues to expect underlying earnings before interest, tax, depreciation and amortisation (EBITDA) of $1,150 million to $1,300 million. This will be down 11% to 21% from $1,459 million in FY 2020.

    Positively, management has upgraded its Integrated Gas guidance for FY 2021. It now expects production of 675-705 PJ, compared to prior guidance of 650-680 PJ. It has also lowered its distribution breakeven to US$25-29/boe, compared to its prior guidance of US$27-31/boe.

    Based on these estimates, management is estimating a free cash flow (FCF) yield of 12% to 15% for FY 2021. It notes that this reflects its resilient businesses with low cost operations and limited near term investment required.

    This bodes well for its dividends, with management noting that its dividend payout ratio will be 30% to 50% of free cash flow.

    Furthermore, it advised that free cash flow surplus cash will be allocated based on the greatest need and highest risk adjusted return. This includes maintaining its target capital structure, investing in growth, and additional returns to shareholders.

    Is Origin a buy?

    One broker that is positive on Origin is UBS. Earlier this month it put a buy rating and $7.40 price target on the company’s shares.

    Based on the current Origin share price, this price target implies potential upside of 41% over the next 12 months excluding dividends.

    It believes its shares are undervalued based on current spot oil prices.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Origin Energy (ASX:ORG) share price on watch after investor update appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/364333l

  • 3 ASX companies named and shamed as worst in industry

    bad asx shares represented by woman hiding face under her jumper

    Three ASX-listed retail giants have been singled out as the worst in the industry for not committing to pay a living wage to factory workers in poverty-stricken countries.

    Myer Holdings Ltd (ASX: MYR), Premier Investments Limited (ASX: PMV) and Mosaic Brands Ltd (ASX: MOZ) were also named in an Oxfam report as the worst-rated companies for transparency of supply chains.

    According to the report titled Shopping for a Bargain, all three ASX businesses continued to hide their supplier factory names and locations to avoid scrutiny. 

    All three refuse to make a “credible, public commitment” to paying living wages to factory workers.

    Twelve major retailers have over the years publicly made a promise to Oxfam that factory workers, who are mostly women living in poverty, would be paid enough to cover basic essentials.

    The Motley Fool has contacted Myer and Premier Investments for comment.

    Mosaic Brands head of compliance, Nic Williams, denied the company refused to participate in the study, saying it offered to “provide the information we could within the bounds of our commercial relationships”.

    “Mosaic Brands requires independent and valid audits of all our factory suppliers,” he told The Motley Fool.

    “Audit requirements that align with our commitments to the ETI Basecode, which includes employment practices, working conditions, and wages and many other factors.” 

    COVID-19 devastated the people who make our clothes

    The report depicted alleged abuse of third-world suppliers by Australian fashion retailers this year when COVID-19 struck.

    “Practically overnight, major global fashion retailers that have profited for decades from paying poverty wages to workers in countries with little social protection and lax labour laws, cancelled orders and delayed or cancelled payments to their suppliers, many demanding discounts on work already completed,” Oxfam stated.

    “In response, factory owners stood down hundreds of thousands of garment workers — approximately 80% of whom are women — without pay, leaving the people who make our clothes without any income, facing a global pandemic in extreme poverty.”

    Some retailers backed down after public outcry from customers and suppliers, and have since paid for orders placed before the pandemic.

    But the initial response demonstrates how Australian retailers can use their power to devastate people already living in abject poverty, stated the report.

    The study was the first detailed inquiry into the supply chains of ten fashion chains operating in Australia with factories in Bangladesh:

    • Best & Less (owned by Pepkor Holdings Ltd (JSE: PPH))
    • Big W (Woolworths Group Ltd (ASX: WOW))
    • Cotton On
    • H & M Hennes & Mauritz AB (STO: HM-B) 
    • Zara (Industria de Diseno Textil SA (BME: ITX))
    • The Just Group (Premier Investments) 
    • Kmart (Wesfarmers Ltd (ASX: WES))
    • Myer
    • Noni B (Mosaic Brands) 
    • Target Australia (Wesfarmers)

    All the companies aside from Myer, Premier and Mosaic had made commitments to pay factory workers a living wage.

    Williams said the study was not “an accurate picture” of how Australian retailers operate in Bangladesh.

    “The report does not state how many Mosaic suppliers were interviewed and does not reflect the extensive safety and wage auditing processes we have in place in Bangladesh and globally.”

    Australians have massive impact on poverty

    Oxfam Australia Chief Executive, Lyn Morgain, said purchasing practices heavily favouring Australian retailers forces third-world factories into poor conditions.

    “These poor purchasing practices of brands are making it impossible for factories to increase wages, despite many of the same brands making public commitments to ensure the payment of living wages,” she said.

    “Instead, wages are trapping workers – mainly women – and their families in a cycle of poverty.”

    The study was conducted with Monash University and University of Liberal Arts Bangladesh. It interviewed both retailers and suppliers for their thoughts.

    Not surprisingly, the retailers always rated themselves better than what the factories did.

    “This may indicate the brands’ failure to fully understand the impact of their purchasing decisions on the factories and the workers in their supply chains.”

    Expensive clothing doesn’t always equate to fair working conditions, according to the report.

    “Clothing production for some of the world’s most luxurious brands is carried out at factories which pay some of the poorest wages.”

    Morgain also called on customers to do their part to pressure retailers into doing the right thing.

    “With just one month today until Christmas, shoppers should demand big brands end this cycle and do better in the way they do business… giving real meaning to their commitments to end poverty wages for the women making our clothes.”

    Forget what just happened. We think this stock could be Australia’s next MONSTER IPO…

    One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…

    Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.

    Returns as of 6th October 2020

    More reading

    Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Premier Investments Limited. The Motley Fool Australia owns shares of Wesfarmers Limited and Woolworths Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 ASX companies named and shamed as worst in industry appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2V43JzG

  • 2 leading ASX growth shares to buy that are falling

    wooden blocks with percentage signs being built into towers of increasing height

    There are some leading ASX growth shares that are seeing falling share prices. The broader e-commerce sector is being sold off.

    Global share markets are rising in response to positive news about COVID-19 vaccines. BioNTech (with Pfizer), Oxford University (with AstraZeneca) and Moderna have all done trials which show the vaccines have a high level of effectiveness.

    However, e-commerce businesses which have seen elevated customer demand during 2020 have seen their share prices fall backwards over the last few weeks.

    But the Motley Fool Share Advisor service still rates the following two ASX growth shares as buys:

    Kogan.com Ltd (ASX: KGN)

    The Kogan.com share price fell by 5.1% yesterday and it has fallen by 35% since 9 November 2020.

    It wasn’t long ago that the company held its annual general meeting (AGM) and gave investors a trading update for the financial year to date to October 2020. The ASX growth shares said that its gross profit was up 99.8%, its gross profit had increased by 131% and adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) had jumped 268.8%.

    There has been a strong performance from its Kogan marketplace and product divisions. The last couple months of the calendar year are important for the company because they include online sales events as well as Christmas. To take advantage of this, Kogan.com has been investing in marketing to increase its customer numbers and grow awareness of the brand. Management believe this will be a long-term positive for the company.

    The CEO and founder of Kogan.com, Ruslan Kogan, said with the FY20 report release: “There is a retail revolution taking place as more and more shoppers learn about the benefits of e-commerce. We’re seeing record numbers of first time customers, who then go on to make repeat purchases at a 40% faster pace than previously. For us this is a very exciting trend that shows that once customers learn about shopping online, they change their ongoing behaviour. Once someone discovers the benefits of online hopping, I struggle to see why they would ever go back to the old way of doing things. After almost 15 years of preparation, the revolution occurring in retail represents a significant opportunity for Kogan.com.”

    According to Commsec estimates, the Kogan.com share price is valued at 24x FY23’s estimated earnings.

    Temple & Webster Group Ltd (ASX: TPW)

    The Temple & Webster share price fell by 9.5% and it has fallen by 22% since 9 November 2020.

    The ASX growth share also recently held its AGM. It said that, on top of 74% revenue growth in FY20, it has grown revenue in the financial year to date (to 19 October) by 138%. It also generated $8.6 million of EBITDA in the first quarter of FY21 which was more than the entire FY20 EBITDA of $8.5 million (which represented growth of 467%). Cashflow was positive in FY20, it finished the year with no debt and $38.1 million of cash. It also grew its active customer number by 77% year on year to 480,000.

    Revenue growth was also in the triple digits at the start of the second quarter of FY21, with growth of more than 100%. In the trading update it said that its contribution margin continued to be ahead of its 15% target with customer satisfaction of around 70%.

    According to Commsec estimates, the Temple & Webster share price is valued at 31x FY23’s estimated earnings.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd and Temple & Webster Group Ltd. The Motley Fool Australia has recommended Kogan.com ltd and Temple & Webster Group Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 leading ASX growth shares to buy that are falling appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3fLYCxH

  • Ask a fund manager: Centuria Healthcare’s Andrew Hemming on unlocking value in Australia’s healthcare properties

    Centuria Capital Group fund manager Andrew Hemming

    With the onset of the COVID-19 pandemic, investor interest in well-positioned ASX healthcare shares and Australian healthcare properties has rocketed.

    There currently are no pureplay ASX-listed healthcare real estate investment trusts (REIT). But there are unlisted funds investing exclusively in Australian healthcare real estate.

    With that in mind, the Motley Fool reached out to fund manager Andrew Hemming, the managing director of Centuria Healthcare.

    Centuria Healthcare, a subsidiary of Centuria Capital Group (ASX: CNI), provides unlisted healthcare property investments to individual, wholesale and institutional investors.

    We were particularly interested in the Centuria Healthcare Property Fund (CHPF). This is a new, open-ended, unlisted fund with a current portfolio of more than $115 million worth of healthcare assets.

    With additional asset purchases in the pipeline, CHPF currently owns the Forrest Family Practice (tenanted by BGH Capital), Bloomfield Medical Centre, Vermont South Medical Centre and Hobart Day Surgery properties (all tenanted by Nexus Hospitals).

    Retail investors can invest with $10,000 or more.

    CHPF’s last distribution for October 2020 was 5.75 Cents Per Unit (CPU), annualised*.

    Read on for the full interview with Andrew Hemming.

    Can you give us an overview of the Centuria Healthcare Property Fund?

    We set the Centuria Healthcare Property Fund with a different structure to what we’ve done before. What we’ve done before are single property and multi-property closed-end funds. This is a multi-property, open-ended fund, with a limited liquidity facility. And with a seed portfolio of roughly $115 million, which we intend on growing with our near-term pipeline and into the future.

    All transactions were off market. Most transactions were operator led, which is an important point of difference for us. In 2013-14, we decided strategically to focus on a partner-based approach to delivering a pipeline of healthcare properties.

    How does the partner-based approach work?

    For example, Nexus Hospitals is one of our aligned partners. Nexus is 75% owned by Queensland Investment Corporation, and 25% owned by doctors and management. They currently operate 15 hospitals, and they’re trying to substantially grow over the next few years than they have over the past, say, seven years. We’re their partner of choice.

    In today’s economic environment, people are wanting to either invest into yield-driven assets or invest into industries that are more robust or resilient. Clearly, we’ve seen over the last 6-8 months that, as a result of COVID, industrial (sheds and warehouses) and healthcare properties (hospitals and medical centres) are attractive.

    We focus on properties that are going to bring us those opportunities, because in our world these opportunities do not typically exist.

    There are a lot of hospitals in Australia, both public and private, where there may be an opportunity to securitise through a sale and leaseback from the operator with a long-term lease into the future, but they don’t exist today.

    So, you’ve got to create the product.

    How do you create that product?

    The best way for us to create our product is through the lens and ability of the operator.

    As in the example with Nexus, the operator is a business with a high degree of capitalisation, vast experience in terms of management prowess as well as clinical experience, like surgeons and nurses. Those are highly specialised assets.

    We work very much in partnership with the operator to find the right location and to create the product type… the opportunity. In creating these healthcare real estate opportunities, we have a highly skilled team in finding, structuring and developing to own the real estate over the long term.

    There are several ways we are able to structure and fund these transactions:

    First, a straight forward sale-and-leaseback where the healthcare operator sells its property with a long-term lease in place.

    Second, a fund-through structure where we would buy the land with leases in place, fund the construction, and own the property over the long-term.

    Or third, as we’ve done more recently, we may come upstream in terms of risk and develop the property. We would ensure we have the anchor tenant with a lease in place which provides us with greater clarity in which other healthcare users can pack around that healthcare operator.

    Let’s say a well-known operator has interest in a site, and the operator has the doctors as well. It will likely occupy 50% of this development. We would acquire the land with 50% leased to this operator. We would then set about leasing the remaining space with complementary healthcare businesses, and in doing so create a sustainable healthcare ecosystem.   

    This strategy is very similar to neighbourhood shopping centres, if you have a core user there.

    The other tenants would be a GP primary care business, a radiology business, a pharmacy, consulting suites, maybe even radiation oncology. They’re all complementary businesses to the anchor tenant.

    And the fund paid a 5.75 CPU annualised distribution in October. How did you determine that and what’s the outlook?

    We arrived at the number for 2 reasons. One, because the off-market seed portfolio we delivered to this fund had a weighted market capitalisation rate of 6.06%, therefore we were able to deliver a 5.75 CPU annualised distribution in October.

    As for the future? With interest rates and the overall economy being weaker, we expect there’ll be a flight to quality. We expect cap rates in healthcare properties will compress, because there’ll be more interest in them. There’ll be a weight of money moving into this space. More than we’ve seen historically.

    We’ll continue to do these deals off market. We are still confident, at least in the next 6-12 months, in acquiring new properties for this fund at an accretive capitalisation rate of 5.75%, because they’ll be off market deals and we’ll be doing them efficiently. Along with existing property acquisitions, we intend on continuing  to buy land and funding construction, creating the benefit of reduced tax leakage from stamp duty.

    Are the Centuria Healthcare Property Fund’s tenants different from those in other sectors?

    These are highly specialised assets in which you’ve got alignment from the customer on the demand side as well as the user, who’s the tenant. The tenant is likely to be there for more than the initial lease term.

    For example, there is the radiation oncology bunker that we built and own in Concord West (Sydney). The tenant spent $15 million on 1 piece of equipment. They’ve also spent an additional $5­-7 million on the other warm shell fit out of that hospital. The equipment is housed in  1.5m thick concrete bunkers which are not going anywhere.

    So that business makes the economic decision on whether they want to be there or not based on the type of demand and the density of that demand. As well locationally, this is a business that’s not too far away from the public hospital that’s just had $341 million spent on it in Concord.

    These are businesses that look at the type of population, the economics of that population, the ancillary services within the building and in the location. And if they think their business is going to be there for a longer period of time, 20 years, if not longer, they are prepared to spend quite a bit of money on their fit out and pieces of equipment.

    And that makes them sticky.

    What essential boxes does a healthcare asset need to tick before you’d consider buying it?

    We really look at the layers of alignment. You want to look at the demographics. You’ve got to be able to build something that’s more specialised than you think it’s going to be used for over time if the population’s going to be there.

    No matter what, it’s not transient. Not like a mining town, which is a transient population in boom or bust cycle. So, we look at the depth and type of demand.

    And we evaluate the type of use and the covenant. The covenant for us is not just the financial capacity of that operator tenant over that period of time, but also its reputation.

    We would look at the strength of the covenant from a financial perspective as well as its ability in terms of experience to drive that type of business model over 20-30 years.

    Then we look at what we can pack around it. You’ve got a high-grade covenant – a blue chip hospital, for example – what other uses and services can you pack around that hospital to make it stronger?

    People talk about ecosystems. This translates to referral networks that work between a primary care business, a hospital business, a radiology business, a pharmacy and a consultancy. They’re all relying on each other to attract that customer. And once that customer’s there, that customer is likely to stay in that building and spend more money. So from an economic viewpoint it’s quite efficient and more sustainable in nature.

    Lastly, from the built form, there are builders that have got good depth of experience in terms of building a hospital or radiation oncology bunker and those who just don’t.

    Has COVID-19 changed your investment criteria? And how has it impacted your tenants?

    Healthcare tenants have been more robust and resilient than other sectors for obvious reasons.

    Even when the Federal Government shut the doors on elective surgery, volume has since recovered (and in some cases surged past previous levels).  This is a result of the pent-up demand.  

    COVID-19’s taught the healthcare sector some important lessons in terms of isolation. Aged care has been impacted quite materially from COVID-19, and the thinking has already started into how to contain the spread of infectious disease in the future. In surgical hospitals, it will be about ventilation systems and improved sterilisation units, for example.

    COVID-19 has taught every industry that being nimble, having a nimble balance sheet, is vitally important.

    That goes to operating their business more effectively.

    One thing is to get cash for a sale and leaseback. That’s great, but what do you do with it?

    You want to invest it into things that are going to make your business better. To make the experience of the customer, the patient, better. Both from a financial efficiency perspective and a health outcome perspective.

    There hasn’t been a listed healthcare REIT on the ASX since 2017. What are your views on this?

    Certainly, there’s a gap in the listed environment for pureplay healthcare property. I think there’s plenty of demand, and it’s a matter of when not if. I think there’s an opportunity for more than 1 manager to have a listed healthcare fund.

    (* Investors should note that past performance is not a reliable indicator of future performance.)

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Ask a fund manager: Centuria Healthcare’s Andrew Hemming on unlocking value in Australia’s healthcare properties appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/33fx8v4

  • Broker tips Fisher & Paykel Healthcare (ASX:FPH) share price to go even higher

    is it a buy

    The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price has been a very strong performer in 2020.

    Since the start of the year, the medical device company’s shares have risen a remarkable 50%.

    Why is the Fisher & Paykel Healthcare share price up 50% this year?

    Investors have been scrambling to buy Fisher & Paykel Healthcare’s shares this year after the COVID-19 pandemic led to a surge in its sales and profits.

    Yesterday, the company released its half year results and revealed a 59% increase in operating revenue to NZ$910.2 million and an 86% jump in net profit after tax to NZ$225.5 million.

    This was driven by strong demand for its hospital hardware, particularly its Optiflow and Airvo systems. Traditionally, this nasal high flow therapy is used in clinical practices but has shifted as a front-line treatment for COVID-19 patients in hospitals.

    Management appears optimistic that the second half will be strong and has lifted its expectations for FY 2021.

    Based on current assumptions, it estimates that full year revenue could come in at NZ$1.72 billion and net profit after tax would be between NZ$400 million to NZ$415 million. The latter is up from its previous expectation for profit after tax of NZ$365 million to NZ$385 million. 

    Is it too late to buy Fisher & Paykel Healthcare shares?

    According to one leading broker, it’s not too late to make an investment in Fisher & Paykel Healthcare’s shares.

    This morning analysts at Goldman Sachs retained their buy rating and bumped their price target higher to $37.60.

    The broker notes that high-flow therapy continues to build momentum and it sees an attractive penetration runway ahead.

    Goldman commented: “High-flow penetration of conventional oxygen therapy probably sits between 10-20%, and we see limited reasons why 50%+ is not possible over the mid/long-term. Clinical and regulatory feedback have been increasingly supportive, and we expect the forward penetration trajectory to have steepened through recent periods.”

    “FPH reiterated today that Optiflow and Airvo are ‘nowhere near’ market saturation. FPH upgraded FY21 guidance for the second time today (after four upgrades in FY20). With near-term momentum accelerating rather than slowing, we expect at least one further upgrade in the remainder of the year and upgrade our FY21 earnings estimate by 11% to $426m (+5% above mid-point of range),” it added.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Broker tips Fisher & Paykel Healthcare (ASX:FPH) share price to go even higher appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3q1vKGb

  • 2 exciting mid cap ASX shares to buy

    Earlier this week I looked at a couple of small cap ASX shares that have been rated as ones to buy.

    But due to the risk that small caps carry, not everyone is comfortable investing at that side of the market.

    With that in mind, today I am moving a little further down the risk scale to mid cap shares.

    Two mid cap ASX shares that are highly rated are listed below. Here’s what you need to know about them:

    Megaport Ltd (ASX: MP1)

    Megaport is a provider of elastic interconnection services across data centres globally. Its clever service allows its users to increase and decrease their available bandwidth in response to their own demand requirements. This is proving to be an increasingly popular alternative to being tied to fixed service levels on long-term and expensive contracts. So much so, in FY 2020 Megaport reported a 57% increase in monthly recurring revenue (MRR) to $5.7 million.

    Analysts at UBS have been encouraged by its new ports growth in FY 2021. They believe this is a sign that its growth is back on track and continue to expect Megaport to benefit from a structural shift to the cloud. In light of this, last month they upgraded its shares to a buy rating with a $16.45 price target.

    Nearmap Ltd (ASX: NEA)

    Nearmap is a $1.1 billion aerial imagery technology and location data company. Its leading products give businesses instant access to high resolution aerial imagery, city-scale 3D datasets, and integrated geospatial tools. This means users can undertake virtual site visits from across the country, which enables informed decisions, streamlined operations, and meaningful cost savings. Nearmap has recently bolstered its offering with the launch of new products. This includes an artificial intelligence product which could be a game-changer in the industry.

    While FY 2020 was a mixed year for Nearmap, analysts at Morgan Stanley expect better in FY 2021. As a result, earlier this month the broker put an overweight rating and $3.10 price target on Nearmap’s shares.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of June 30th

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends MEGAPORT FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nearmap Ltd. The Motley Fool Australia has recommended MEGAPORT FPO and Nearmap Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 exciting mid cap ASX shares to buy appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/363in0m

  • 2 ASX dividend shares with 6%+ yields to buy

    man handing over wad of cash representing microsoft dividend

    Luckily for income investors in this low interest rate environment, there are a large number of dividend shares to choose from on the Australian share market.

    But with all the quality options, it can be hard to decide which ones to buy.

    Two ASX dividend shares with 6%+ yields that come highly rated are listed below:

    Aventus Group (ASX: AVN)

    Although the retail sector has been a difficult place to be this year because of the pandemic, particularly in respect to property, Aventus has been largely unaffected. This is thanks to the popularity of its retail parks with consumers and their high weighting towards everyday needs. Among its tenants you’ll find retailers such as ALDI, Bunnings, Officeworks, and The Good Guys.

    One broker that has been impressed with its performance and expects more of the same in the future is Goldman Sachs. It recently reiterated its buy rating and $2.76 price target on its shares. It notes that Aventus has a quality portfolio and opportunities with its land bank. And based on the latest Aventus share price, the broker estimates that it offers a forward 6.2% dividend yield.

    Fortescue Metals Group Limited (ASX: FMG)

    This iron ore producer could offer one of the most generous dividend yields on the Australian share market right now. This is thanks to the high levels of free cash flow the company is generating due to sky high iron ore prices and its ultra low costs. At the time of writing, the benchmark iron ore price is up slightly to US$123.180 a tonne. This compares to Fortescue’s current C1 costs of just US$12.74 per wet metric tonne.

    Last week analysts at Macquarie reaffirmed their outperform rating and $20.00 price target due to the high iron ore prices. They estimate that its free cash flow generation will allow the Fortescue board to declare a dividend of approximately $1.64 per share in FY 2021. Based on the latest Fortescue share price, this equates to a fully franked 8.8% dividend yield.

    These Dividend Stocks Could Be Your Next Cash Kings (FREE REPORT)

    Motley Fool Australia’s Dividend experts recently released a brand-new FREE report revealing 3 dividend stocks with JUICY franked dividends that could keep paying you meaty dividends for years to come.

    Our team of investors think these 3 dividend stocks should be a ‘must consider’ for any savvy dividend investor. But more importantly, could potentially make Australian investors a heap of passive income.

    Don’t miss out! Simply click the link below to grab your free copy and discover these 3 high conviction stocks now.

    Returns As of 6th October 2020

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended AVENTUS RE UNIT. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 ASX dividend shares with 6%+ yields to buy appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/33h7O88